Centocor T18 Study
- Date:
- 1995-1998
- Reference:
- SA/KET/A/1/5
- Part of:
- The Kennedy Trust for Rheumatology Research
- Archives and manuscripts
Collection contents
About this work
Description
Comprises papers relating to the single centre, open label C0168T18 study "Tumor Necrosis Factor (TNF) Blockade in Patients with Rheumatoid Arthritis: Mechanisms of Action."
The study was designed to further investigate the effectiveness of cA2. It was sponsored by Centocor and led by the Kennedy Institute of Rheumatology, with investigators Ravinder Maini, Marc Feldmann and Dr M. Elliott and Dr M. Peters. The study aimed to determine the effect of a single 10mg/kg infusion of cA2 on the cells of joints in patients with active rheumatoid arthritis.10 patients were enrolled in the study for a period of 12 weeks which took place in an outpatient setting at Charing Cross Hospital, Hammersmith Hospital and the Kennedy Institute of Rheumatology.
See SA/KET/A/2 for further Centocor research collaboration papers.